Earlier HPV vaccination linked to lower cervical cancer incidence
A large population review examined cancer outcomes and specific safety concerns, with uncertainty varying by outcome and study design.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
HPV vaccination was associated with lower cervical cancer incidence, with stronger results among those vaccinated in early adolescence. The review rated this evidence as moderately certain. It also found no association with increased risk for several assessed adverse outcomes, but those findings do not answer every safety question or establish causation from observational comparisons.
Bias ratings ranged from moderate to critical, and cervical cancer estimates varied across studies. These limitations matter when interpreting adjusted observational associations, even in a very large review.
What researchers found
Cervical cancer incidence
Among females vaccinated by age 16, long-term cervical cancer risk was 0.20 times the cohort comparator risk. Comparator details were unspecified. This relative measure does not give an absolute percentage-point reduction.
What the abstract covers
The review brought together studies using several designs and pooled estimates adjusted for confounding. Cancer findings therefore draw on comparisons in populations, with different possible sources of bias.
Safety findings have boundaries
For infertility and premature ovarian failure, the review found no association with increased risk. Guillain-Barré syndrome evidence was less certain, and no studies reported community rates of serious adverse events.
The original publication
Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination.
Henschke N, Bergman H, Buckley BS et al.
Cochrane Database Syst Rev · 2025
- PubMed ID
- 41276264
- Record checked
Linked publication notices
- UpdateOf
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.